The Renaissance of Natural Products as Drug Candidates

By I. Paterson, E. Anderson. Science, 2005

522 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Control of plant diseases by natural products: Allicin from garlic as a case study (2008, background): “” The authors go on to state that “Despite this statistic pharmaceutical companies have embraced the era of combinatorial chemistry, neglecting the development of natural products as potential drug candidates in favour of high-throughput synthesis of large compound libraries” (Peterson and Anderson ”
Reducing emissions from deforestation - the "combined incentives" mechanism and empirical simulations. (2009, background): “To focus on just one aspect, a recent review showed that 47% of the small molecules used in cancer treatment in the US are either natural products or were directly derived from them (Newman and Cragg, 2007) and the role of these in the pharmaceutical sector has been reaffirmed (Paterson and Anderson”
Discovery and resupply of pharmacologically active plant-derived natural products: A review (2015, methodology): “…and analytical equipment, increasing number of targets available for testing, and improved possibilities for optimization of natural leads using synthetic modification strategies [reviewed in (Henrich and Beutler, 2013; Koehn and Carter, 2005; Li and Vederas, 2009; Paterson and Anderson, 2005)].”
Natural products as leads to anticancer drugs (2007, background): “pounds with pharmacological activity and extraordinary therapeutic possibilities [6–11].”